


**Prior Authorization Review Panel
MCO Policy Submission**

A separate copy of this form must accompany each policy submitted for review.
Policies submitted without this form will not be considered for review.

Plan: AmeriHealth Caritas Pennsylvania and Keystone First	Submission Date: 11/1/2024
Policy Number: ccp.1024	Effective Date: 9/2013 Revision Date: October 1, 2024
Policy Name: Chromosomal microarray analysis in prenatal and postnatal care	
Type of Submission – Check all that apply: ☐ New Policy ☒ Revised Policy* ☐ Annual Review – No Revisions ☐ Statewide PDL	
*All revisions to the policy <u>must</u> be highlighted using track changes throughout the document. Please provide any clarifying information for the policy below: See tracked changes below.	
Name of Authorized Individual (Please type or print): Manni Sethi, MD, MBA, CHCQM	Signature of Authorized Individual: 

Chromosomal microarray analysis in prenatal and postnatal care

Clinical Policy ID: CCP.1024

Recent review date: 10/2024

Next review date: 2/2026

Policy contains: Chromosomal microarray analysis, comparative genomic hybridization, developmental delay, karyotyping, single nucleotide polymorphism.

AmeriHealth Caritas Pennsylvania has developed clinical policies to assist with making coverage determinations. AmeriHealth Caritas Pennsylvania clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and peer-reviewed professional literature. These clinical policies along with other sources, such as plan benefits and state and federal laws and regulatory requirements, including any state- or plan-specific definition of “medically necessary,” and the specific facts of the particular situation are considered by AmeriHealth Caritas Pennsylvania on a case by case basis when making coverage determinations. In the event of conflict between this clinical policy and plan benefits and/or state or federal laws and/or regulatory requirements, the plan benefits and/or state and federal laws and/or regulatory requirements shall control. AmeriHealth Caritas Pennsylvania clinical policies are for informational purposes only and not intended as medical advice or to direct treatment. Physicians and other health care providers are solely responsible for the treatment decisions for their patients. AmeriHealth Caritas Pennsylvania clinical policies are reflective of evidence-based medicine at the time of review. As medical science evolves, AmeriHealth Caritas Pennsylvania will update its clinical policies as necessary. AmeriHealth Caritas Pennsylvania clinical policies are not guarantees of payment.

Coverage policy

Chromosomal microarray analysis is clinically proven and, therefore, may be medically necessary when all of the following criteria are met (American College of Obstetricians and Gynecologists, 2016, 2020):

- Any of the following indications:
 - Evaluation of a fetus with one or more major structural abnormalities identified on ultrasonographic examination who is undergoing invasive prenatal diagnosis.
 - Evaluation of a structurally normal fetus who is undergoing invasive prenatal diagnostic testing.
 - Postnatal evaluation of members with unexplained developmental delay/intellectual disabilities, autism spectrum disorder, or multiple congenital anomalies.
 - After fetal death or stillbirth, testing fetal tissue to conduct further cytogenetic analysis to improve detection of causative abnormalities.
- An obstetrician-gynecologist or other health care provider with expertise in genetics provides pre-test and post-test genetic counseling to the member on benefits, limitations, and results of chromosomal microarray analysis.
- Informed consent, including discussion of the potential to identify findings of uncertain significance, non-paternity, consanguinity, and adult-onset disease, is given along with the chromosomal microarray

analysis.

Limitations

No limitations were identified for this policy.

Alternative covered services

Clinical evaluation by a network medical geneticist, neurologist, and other qualified specialist or by the primary care physician constitutes covered services.

Background

Conventional karyotyping, specifically G-banded karyotyping, has been the accepted first-line test for detecting large changes in the structure or number of whole chromosomes in newborns (e.g., translocations, aneuploidy) (Miller, 2010). Advances in molecular testing methods, such as chromosomal microarray analysis and next-generation sequencing, permit improved detection of chromosomal variants at a much higher resolution level in fetuses and newborns.

Chromosomal microarray analysis detects deletions and duplications of one or more sections of deoxyribonucleic acid (known as copy number variations). It is also known as cytogenomic microarray analysis, microarray-based genomic copy-number analysis, or molecular karyotyping, and collectively describes two different laboratory techniques (Miller, 2010):

- Array comparative genomic hybridization, which detects copy number variations for relatively large deletions or duplications, including whole chromosome duplications, as in trisomy.
- Single nucleotide variant arrays, which detect specific known deoxyribonucleic acid sequence variants.

Chromosomal microarray analysis does not detect balanced chromosome rearrangements in which there is no gain or loss of deoxyribonucleic acid (e.g., balanced inversions or balanced translocations). Chromosomal microarray may also detect copy variants of unclear clinical significance, and it may detect a variant with one or more genes related to health problems that were not the reason for testing (Ahn, 2015; Shao, 2021).

In the prenatal setting, chromosomal microarray analysis requires an invasive procedure to collect intact fetal cells (e.g., amniocentesis or chorionic villous sampling) (Shao, 2021). Blood samples can be used for infants and children (Miller, 2010).

Approvals from the U.S. Food and Drug Administration for chromosomal microarray analysis devices were granted for CytoScan® Dx Assay in 2014, and GenetiSure Dx Postnatal Assay in 2017 (U.S. Food and Drug Administration, 2014, 2017).

Findings

Guidelines

The role of chromosomal microarray analysis relative to conventional karyotyping and next-generation sequencing in prenatal and newborn care continues to evolve. While higher resolution molecular testing increases the detection of chromosomal variants over that of karyotyping, it also increases detection of variants of uncertain significance and other incidental findings, creating uncertainty in interpreting and applying the information into health care decisions.

Additional testing after a normal or abnormal chromosomal microarray analysis may be needed to clarify the results or to identify genomic events that chromosomal microarray cannot detect, such as balanced rearrangements, possible mosaicism, or the genetic mechanism associated with a copy number variation. This

suggests a complementary role for chromosomal microarray analysis in certain fetal diagnoses and for newborns with neurodevelopmental issues and birth defects (Waggoner, 2018; Klapwijk, 2021).

To mitigate the uncertainty, guidelines emphasize the importance of local policy and protocols, providing phenotype information, understanding the strengths and limitations of molecular testing, multidisciplinary consultation, using trio analysis to aid in interpretation and pre- and post-test genetic counselling (Klapwijk, 2021).

A 2010 guideline by the International Standard Cytogenomic Array Consortium that followed a systematic review of 33 studies endorsed chromosomal microarray testing, as opposed to G-banded karyotyping, as a first-line diagnostic method for developmental delay/intellectual disabilities, autism spectrum disorder, or multiple congenital anomalies (Miller, 2010).

An American College of Medical Genetics guideline, recognizing that a genetic basis for autism can be found in 30% to 40% of cases, recommended that chromosomal microarray testing be considered a first-tier test in place of a karyotype for individuals with developmental disabilities or congenital anomalies. In the genetic evaluation of autism, its diagnostic yield is approximately 10% and complements other molecular testing. Genetic testing should be discussed with all patients and families with autism spectrum disorder (Schaefer, 2013).

A December 2016 Committee Opinion from the American College of Obstetricians and Gynecologists recommended prenatal chromosomal microarray analysis for women of all ages. The College recommended the analysis for fetuses with one or more major structural abnormalities found on ultrasound, in structurally normal fetuses undergoing diagnostic testing, and in evaluation of intrauterine fetal death or stillbirth to better understand cause (American College of Obstetricians and Gynecologists, 2016).

The American College of Obstetricians and Gynecologists (2020) issued a strong recommendation for incorporating microarray analysis into the stillbirth workup to improve test success rate and detection of genetic anomalies compared with conventional karyotyping.

The Society for Maternal-Fetal Medicine recommended that women be offered fetal diagnostic testing, including chromosomal microarray analysis, when fetal growth restriction is detected and a fetal malformation, polyhydramnios, or both are also present regardless of gestational age. The Society also recommends that pregnant women be offered prenatal diagnostic testing with chromosomal microarray analysis when unexplained isolated fetal growth restriction is diagnosed prior to 32 weeks gestation (Martins, 2020).

The American College of Medical Genetics and Genomics updated their technical laboratory standards in 2021. The standards presented the advantages and limitations of chromosome microarray analysis and confirmed the indications established by the American College of Medical Genetics and Genomics, American College of Obstetricians and Gynecologists, and the Society for Maternal–Fetal Medicine (Shao, 2021).

Evidence review

The following systematic reviews, meta-analyses, and other large-scale studies offered evidence on the efficacy of chromosomal microarray analysis. The most frequent fetal anomalies studied were congenital heart diseases, multiple malformations, and central nervous system malformations detected on fetal imaging and in fetal loss tissue. Studies reported the incidence of normal and abnormal genetic results. There is insufficient evidence quantifying the incremental impact of chromosomal microarray analysis on clinical outcomes or cost benefit. At this time, the benefit of a genetic diagnosis allows for more accurate genetic counseling and informed reproductive decision making.

The evidence suggests chromosomal microarray analysis is more sensitive in detecting the loss or gain of genetic material than karyotyping, with an incremental yield of up to 10% depending on the presence of structural anomalies on ultrasound, but it also detects more variants of unknown significance. On the other hand,

karyotyping detects polyploidy and rearrangements more frequently. Comparison of chromosomal microarray analysis to exome sequencing requires further study. The choice of testing will depend on many factors, including fetal phenotype, maternal and gestational age, and personal and family medical history. However, many of these factors were reported insufficiently in most studies, and their impact on test performance could not be determined.

In non-malformed growth-restricted fetuses, chromosomal microarray analysis had an incremental yield of 4% over karyotyping, rising to 10% in the presence of fetal growth restriction and fetal malformations (Borrell, 2018). In a large prenatal sample (n = 3,223) in whom 54.2% met the American College of Obstetricians and Gynecologists guideline criteria for either chromosomal microarray analysis or karyotype, the incremental yields of chromosomal microarray analysis over karyotyping in the presence of fetal structural abnormality and of no structural abnormality were 4.7% and 2.5%, respectively (Hay, 2018). In fetuses with increased nuchal translucency and normal karyotype, genomic microarray had an incremental yield of 5.0% more copy number variants than karyotyping, which rose to 7.0% when malformations were present (Grande, 2015).

A systematic review/meta-analysis included six studies of pregnant women who received chorionic villus biopsies, amniocentesis, or cordocentesis. The risk of bias in the included studies was mixed. Chromosomal microarray analysis using comparative genomic hybridization had higher sensitivity and similar specificity (0.939 and 0.999) compared to karyotyping (0.626 and 0.999) (Saldarriaga, 2015).

A cost analysis comparing these methods alone and sequentially showed microarray alone appeared to be the preferred cost-effective strategy for sonographically-detected anomalies. Karyotyping alone and chromosomal microarray following a normal karyotype were also acceptable strategies, but performing both tests simultaneously did not appear to improve diagnosis and added more costs (Harper, 2014).

A study of 258 children with autism spectrum disorder found 9.3% and 8.4% received a molecular diagnosis from chromosomal microarray analysis and whole-exome sequencing, respectively. A total of 15.8% of this group received a molecular diagnosis, with only two subjects overlapping in both groups, indicating that testing with both methods is a useful diagnostic tool (Tammimies, 2015).

A meta-analysis of 30 articles on testing for neurodevelopmental disorders compared exome sequencing with chromosomal microarray analysis. The yield of exome sequencing was 36% overall, superior to the 15% to 20% in prior studies of chromosomal array analysis (Srivastava, 2019).

When incorporated into the stillbirth work-up, chromosomal microarray analysis improves the detection of genetic causes compared with conventional karyotyping. The most common pathogenic copy number variant detected was del22q11.21 (Martinez-Portilla, 2019; Pauta, 2018). A meta-analysis comparing molecular testing techniques revealed a 48% prevalence using array-comparative genomic hybridization, compared with 47% for conventional karyotyping, 60% for single nucleotide polymorphism array, 38% for fluorescence in-situ hybridization, and 25% for multiplex ligation-dependent probe amplification. In the setting of pregnancy loss, improved detection of chromosomal abnormalities may not change clinical decision making but may help parents cope with the loss (Smits, 2020).

In 2022, we focused the policy on chromosomal microarray analysis for non-neoplastic conditions encompassing prenatal and postnatal indications. We added to the list of indications postnatal testing for members with unexplained developmental delay/intellectual disabilities, autism spectrum disorder, or multiple congenital anomalies, as recommended by the International Standard Cytogenomic Array Consortium (Miller, 2010).

We added three systematic reviews and meta-analyses that examined the incremental diagnostic yield of chromosomal microarray analysis in diagnosing fetal cardiovascular anomalies (Mastromoro, 2022a, 2022b; Sun, 2021). The new research results confirm previous policy findings and warrant no additional policy changes.

In 2023, we added a recommendation from the American College of Obstetricians and Gynecologists (2020) to

incorporate microarray analysis in stillbirth evaluation. No policy changes are warranted.

In 2024, we reorganized the findings section, deleted older references, and found no newly published relevant literature to add to the policy. No policy changes are warranted.

References

On August 20, 2024, we searched PubMed and the databases of the Cochrane Library, the U.K. National Health Services Centre for Reviews and Dissemination, the Agency for Healthcare Research and Quality, and the Centers for Medicare & Medicaid Services. Search terms were “prenatal diagnosis” (Mesh), “genetic testing” (Mesh), “comparative genomic hybridization,” “chromosomal microarray analysis,” “cytogenomic microarray analysis,” “copy number analysis,” “molecular karyotyping,” and “single nucleotide polymorphisms.” We included the best available evidence according to established evidence hierarchies (typically systematic reviews, meta-analyses, and full economic analyses, where available) and professional guidelines based on such evidence and clinical expertise.

Ahn JW, Coldwell M, Blint S, Ogilvie CM. Array comparative genomic hybridization (array CGH) for detection of genomic copy number variants. *J Vis Exp*. 2015;(96):51718. Doi: 10.3791/51718.

American College of Obstetricians and Gynecologists/Society for Maternal Fetal Medicine. Committee opinion No. 682: Microarrays and next-generation sequencing technology: The use of advanced genetic diagnostic tools in obstetrics and gynecology. *Obstet Gynecol*. 2016;128(6):262-268. Doi: 10.1097/AOG.0000000000001817.

American College of Obstetricians and Gynecologists/Society for Maternal Fetal Medicine. Management of stillbirth: Obstetric care consensus no. 10. *Obstet Gynecol*. 2020;135(3):e110-e132. Doi: 10.1097/AOG.0000000000003719.

Borrell A, Grande M, Pauta M, Rodriguez-Revenga L, Figueras F. Chromosomal microarray analysis in fetuses with growth restriction and normal karyotype: A systematic review and meta-analysis. *Fetal Diagn Ther*. 2018;44(1):1-9. Doi: 10.1159/000479506.

Grande M, Jansen FA, Blumenfeld YJ, et al. Genomic microarray in fetuses with increased nuchal translucency and normal karyotype: A systematic review and meta-analysis. *Ultrasound Obstet Gynecol*. 2015;46(6):650-658. Doi: 10.1002/uog.14880.

Harper LM, Sutton AL, Longman RE, Odibo AO. An economic analysis of prenatal cytogenetic technologies for sonographically detected fetal anomalies. *Am J Med Genet A*. 2014;164A(5):1192-1197. Doi: 10.1002/ajmg.a.36435.

Hay SB, Sahoo T, Travis MK, et al. ACOG and SMFM guidelines for prenatal diagnosis: Is karyotyping really sufficient? *Prenat Diagn*. 2018;38(3):184-189. Doi: 10.1002/pd.5212.

Klapwijk JE, Srebniak MI, Go ATIJ, Govaerts LCPG, et al. How to deal with uncertainty in prenatal genomics: A systematic review of guidelines and policies. *Clin Genet*. 2021;100(6):647-658. Doi: 10.1111/cge.14010. Epub 2021 Jun 30.

Martinez-Portilla RJ, Pauta M, Hawkins-Villareal A, et al. Added value of chromosomal microarray analysis over conventional karyotyping in stillbirth work-up: Systematic review and meta-analysis. *Ultrasound Obstet Gynecol*. 2019;53(5):590-597. Doi: 10.1002/uog.20198.

- Martins JG, Biggio JR, Abuhamad A. Society for Maternal-Fetal Medicine consult series #52: Diagnosis and management of fetal growth restriction: (Replaces Clinical Guideline Number 3, April 2012). *Am J Obstet Gynecol*. 2020;223(4):B2-B17. Doi: 10.1016/j.ajog.2020.05.010.
- Mastromoro G, Guadagnolo D, Hashemian NK, Marchionni E, Traversa A, Pizzuti A. Molecular approaches in fetal malformations, dynamic anomalies and soft markers: Diagnostic rates and challenges-systematic review of the literature and meta-analysis. *Diagnostics (Basel)*. 2022;12(3):575. Doi: 10.3390/diagnostics12030575.(a)
- Mastromoro G, Hashemian NK, Guadagnolo D, et al. Chromosomal microarray analysis in fetuses detected with isolated cardiovascular malformation: A multicenter study, systematic review of the literature and meta-analysis. *Diagnostics (Basel)*. 2022;12(6):1328. Doi: 10.3390/diagnostics12061328.(b)
- Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. *Am J Hum Genet*. 2010;86(5):749-764. Doi: 10.1016/j.ajhg.2010.04.006.
- Pauta M, Grande M, Rodriguez-Revena L, Kolomietz E, Borrell A. Added value of chromosomal microarray analysis over karyotyping in early pregnancy loss: Systematic review and meta-analysis. *Ultrasound Obstet Gynecol*. 2018;51(4):453-462. Doi: 10.1002/uog.18929.
- Saldarriaga W, Garcia-Perdomo H, Arango-Pineda J, Fonseca J. Karyotype versus genomic hybridization for the prenatal diagnosis of chromosomal abnormalities: A meta-analysis. *Am J Obstet Gynecol*. 2015;212(3):330.e1-10. Doi: 10.1016/j.ajog.2014.10.011.
- Schaefer G, Mendelsohn N. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. *Genet Med* 2013;15(5):399–407. Doi: 10.1038/gim.2013.32.
- Shao L, Akkari Y, Cooley LD, et al. Chromosomal microarray analysis, including constitutional and neoplastic disease applications, 2021 revision: A technical standard of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2021;23(10):1818-1829. Doi: 10.1038/s41436-021-01214-w.
- Smits MAJ, van Maarle M, Hamer G, Mastenbroek S, Goddiin M, van Wely M. Cytogenomic testing of pregnancy loss tissue: A meta-analysis. *Reprod Biomed Online*. 2020;40(6):867-879. Doi: 10.1016/j.rbmo.2020.02.001.
- Srivastava S, Love-Nichols JA, Dies KA, et al. Meta-analysis and multidisciplinary consensus statement: Exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. *Genet Med*. 2019;21(11):2413-2421. Doi: 10.1038/s41436-019-0554-6.
- Sun Y, Zhang W, Wang Z, Guo L, Shi S. Chromosomal microarray analysis vs. karyotyping for fetal ventriculomegaly: A meta-analysis. *Chin Med J (Engl)*. 2021;135(3):268-275. Doi: 10.1097/CM9.0000000000001683.
- Tammimies K, Marshall CR, Walker S, et al. Molecular diagnostic yield of chromosomal microarray analysis and whole-exome sequencing in children with autism spectrum disorder. *JAMA*. 2015;314(9):895-903. Doi: 10.1001/jama.2015.10078.
- U.S. Food and Drug Administration. CytoScan Dx Assay approval letter. https://www.accessdata.fda.gov/cdrh_docs/pdf13/K130313.pdf. Published January 21, 2014.
- U.S. Food and Drug Administration. GenetiSure Dx Postnatal Assay approval letter. https://www.accessdata.fda.gov/cdrh_docs/pdf16/K163367.pdf. Published August 11, 2017.
- Waggoner D, Wain KE, Dubuc AM, et al. on behalf of the ACMG Professional Practice and Guidelines Committee. Yield of additional genetic testing after chromosomal microarray for diagnosis of neurodevelopmental disability and congenital anomalies: A clinical practice resource of the American College

Policy updates

5/2013: initial review date and clinical policy effective date: 9/2013

9/2014: Policy references updated.

9/2015: Policy references updated.

9/2016: Policy references updated.

9/2017: Policy references updated.

9/2018: Policy references updated.

10/2019: Policy references updated. Policy ID changed to CCP.1024.

10/2020: Policy references updated.

10/2022: Policy references updated. Policy title and coverage modified.

10/2023: Policy references updated.

10/2024: Policy references updated.